Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

For people living with Type 1 Diabetes, keeping blood sugar levels in check is a constant challenge. A new clinical trial at ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

The pen needles market valued at US$ 1.69 Billion in 2023, is forecasted to grow at a robust CAGR of 9.2%, reaching US$ 1.81 Billion in 2024 ...

The pen needles market valued at US$ 1.69 Billion in 2023, is forecasted to grow at a robust CAGR of 9.2%, reaching US$ 1.81 ...

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

For five years, insulin manufacturer Novo Nordisk agrees to cap out-of-pocket cost of its insulin treatments at $35 per month, and provide free insulin to the neediest Minnesotans.

The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic ... persons with type 2 diabetes. It is designed as an injectable solution for subcutaneous delivery.

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...